First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Dong-Wan Kim, Yi-Long Wu, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D Wilner, Jennifer Tursi, M Boyer (Collaborator), V Ganju (Collaborator), B Hughes (Collaborator), N Pavlakis (Collaborator), B Solomon (Collaborator), S Varma (Collaborator), T Berghmans (Collaborator), J-L Canon (Collaborator), I Demedts (Collaborator), A Janssens (Collaborator), R Louis (Collaborator), T Pieters (Collaborator)D Schallier (Collaborator), V Surmont (Collaborator), C Maciel da Silva (Collaborator), C-G Moreira Ferreira (Collaborator), V Hirsh (Collaborator), A Joy (Collaborator), F Laberge (Collaborator), W Morzycki (Collaborator), R Wierzbicki (Collaborator), B Han (Collaborator), X Liu (Collaborator), S Qin (Collaborator), Y Shi (Collaborator), Y Wang (Collaborator), G Wu (Collaborator), Y-L Wu (Collaborator), C Zhou (Collaborator), J Ahvonen (Collaborator), F Barlesi (Collaborator), J Cadranel (Collaborator), E Dansin (Collaborator), J Fayette (Collaborator), J-F Morere (Collaborator), D Moro-Sibilot (Collaborator), J-L Pujol (Collaborator), E Quoix (Collaborator), G Zalcman (Collaborator), N Frickhofen (Collaborator), C-P Schneider (Collaborator), T Wehler (Collaborator), T Mok (Collaborator), P So (Collaborator), S Cuffe (Collaborator), A Bearz (Collaborator), C Boni (Collaborator), F Cappuzzo (Collaborator), F Cognetti (Collaborator), F De Braud (Collaborator), T De Pas (Collaborator), D Galetta (Collaborator), M Migliorino (Collaborator), D Rocco (Collaborator), G Scagliotti (Collaborator), P Tagliaferri (Collaborator), M Tiseo (Collaborator), K Aoe (Collaborator), T Hida (Collaborator), T Kato (Collaborator), T Kozuki (Collaborator), K Nakagawa (Collaborator), S Niho (Collaborator), M Nishio (Collaborator), H Nokihara (Collaborator), M Satouchi (Collaborator), T Seto (Collaborator), T Takahashi (Collaborator), J-S Ahn (Collaborator), D-W Kim (Collaborator), S-W Kim (Collaborator), G Berchem (Collaborator), O Arrieta Rodriguez (Collaborator), B Biesma (Collaborator), A-M Dingemans (Collaborator), E Smit (Collaborator), A Helland (Collaborator), F Barata (Collaborator), V Gorbunova (Collaborator), G Manikhas (Collaborator), S Orlov (Collaborator), S Leong (Collaborator), H-L Lim (Collaborator), R Soo (Collaborator), E-H Tan (Collaborator), A Nosworthy (Collaborator), M Codes Villena (Collaborator), E Felip (Collaborator), P Garrido Lopez (Collaborator), D Isla Casado (Collaborator), N Martinez Banaclocha (Collaborator), S Ponce Aix (Collaborator), N Reguart Aransay (Collaborator), D Rodriguez Abreu (Collaborator), J Trigo Perez (Collaborator), O Gautschi (Collaborator), M Pless (Collaborator), A Zippelius (Collaborator), G-C Chang (Collaborator), Y-H Tsai (Collaborator), Y Shparyk (Collaborator), F Blackhall (Collaborator), N Steele (Collaborator), V Armenio (Collaborator), K Dragnev (Collaborator), M Dugan (Collaborator), S Gadgeel (Collaborator), D Gerber (Collaborator), S Graziano (Collaborator), S Gurubhagavatula (Collaborator), L Horn (Collaborator), S Jalal (Collaborator), R Lauer (Collaborator), R Mehra (Collaborator), T Mekhail (Collaborator), H Mirshahidi (Collaborator), S Pakkala (Collaborator), J Polikoff (Collaborator), H Raftopoulos (Collaborator), M Saleh (Collaborator), R Salgia (Collaborator), S Waqar (Collaborator), Benjamin Solomon (Collaborator)

    Research output: Contribution to journalArticlepeer-review


    BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS: We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up to six cycles. Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy. The primary end point was progression-free survival as assessed by independent radiologic review. RESULTS: Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P
    Original languageEnglish
    Pages (from-to)2167-2177
    JournalThe New England Journal of Medicine
    Issue number23
    Publication statusPublished - 4 Dec 2014


    Dive into the research topics of 'First-line crizotinib versus chemotherapy in ALK-positive lung cancer.'. Together they form a unique fingerprint.

    Cite this